Why Leading Sponsors Choose PCR Alliance

PCR Alliance was founded in response to growing demand from pharmaceutical and medical device companies seeking high-quality clinical evidence generation in UK primary care settings. We’re proud to partner with the sponsors below, along with many CROs who prefer to keep their collaborations confidential.

Partnership, Not Just Participation

Our approach goes beyond simply providing trial sites. We actively collaborate with sponsors from the earliest stages:

Protocol Development Support — We review study designs to ensure they’re optimized for primary care delivery, identifying potential challenges before they arise.

Real-World Insights — Our GP partners provide invaluable feedback on protocol feasibility, patient burden, and recruitment strategies based on their deep understanding of community populations.

Quality by Design — This collaborative approach enhances study quality, improves participant outcomes, and generates more reliable clinical data that reflects real-world practice.

The Primary Care Advantage

Rapid Patient Identification — Our GP practices leverage electronic health records (EHRs) to quickly identify and contact eligible participants who meet study criteria, dramatically reducing recruitment timelines.

Established Patient Relationships — GPs already know their patients’ medical histories, conditions, and suitability for trials, enabling faster, more accurate screening.

Community Understanding — Our sites understand the unique demographics, health challenges, and cultural considerations within their communities, allowing for tailored participant engagement and retention strategies.

Accessibility — Patients prefer participating in trials at their local GP surgery rather than traveling to distant hospital sites, improving recruitment and retention rates.

Proven Track Record

• 2-8 week average setup time vs. 6-12 months for traditional routes through NIHR
• 100% MHRA & GCP compliance across all partner practices
• High patient satisfaction rates due to local, convenient participation
• Strong retention rates through established GP-patient relationships

The result? Faster trials, higher quality data, and better patient outcomes — all delivered in the communities where your treatments will ultimately be used.